JOHNSON DAVID LEE
Chief Operating Officer
JOHNSON DAVID LEE has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Feb 25, 2026.
On the most recent filing, JOHNSON DAVID LEE is listed as Chief Operating Officer at Vera Therapeutics, Inc. Inside the rolling window, JOHNSON DAVID LEE reported no open-market purchases and 1 open-market sale totaling $108K in VERA.
Companies traded
Other insiders at VERA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$108K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has JOHNSON DAVID LEE made?
JOHNSON DAVID LEE has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does JOHNSON DAVID LEE trade?
JOHNSON DAVID LEE has filed SEC Form 4 disclosures for 1 company, including VERA.
When was JOHNSON DAVID LEE's most recent SEC Form 4 filing?
JOHNSON DAVID LEE's most recent SEC Form 4 filing on Tracefour is dated Feb 25, 2026.
What is JOHNSON DAVID LEE's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, JOHNSON DAVID LEE is listed as Chief Operating Officer.
What is JOHNSON DAVID LEE's total buy and sell value in the current window?
Inside the rolling retention window, JOHNSON DAVID LEE bought $0 and sold $108K based on SEC Form 4 filings.
What was JOHNSON DAVID LEE's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,579 VERA shares on 2026-02-23, worth $108K, per SEC Form 4 filings.